CDMO News
Jazz Pharmaceuticals Expands Portfolio with Redx Pharma’s KRAS Inhibitor
Jazz Pharmaceuticals has made a strategic move in the pharmaceutical industry by entering into a definitive agreement with Redx Pharma. This agreement involves the acquisition of global rights to the KRAS inhibitor program, a significant development in the field of contract